Wednesday, January 23, 2019
Eidos Therapeutics downgraded to Neutral from Overweight at JPMorgan
Eidos Therapeutics downgraded to Neutral from Overweight at JPMorgan. JPMorgan analyst Rama downgraded Eidos Therapeutics to Neutral from Overweight with an unchanged price target of $29. The analyst continues to believe AG10 “will emerge as a best in class stabilizer with time,” but he views 2019 as “more of an execution year.” Eidos shares will be a “relative Neutral” in the first half of 2019 while remaining attractive for investors with a multi-year horizon, says Rama.
https://thefly.com/landingPageNews.php?id=2852323
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.